×
About 2,015 results

ALLMedicine™ Primary Central Nervous System Lymphoma Center

Research & Reviews  687 results

Longitudinally extensive transverse myelitis preceding primary central nervous system l...
https://doi.org/10.1080/10790268.2022.2087137
The Journal of Spinal Cord Medicine; Ser MH, Güleç B et. al.

Jun 28th, 2022 - 65-year-old female diagnosed with longitudinally extensive transverse myelitis. She had excellent response to immunotherapy despite her atypical features, and her spinal lesion was fully recovered in the second month of the treatment. Nine months ...

FDA approves liso-cel as second-line therapy for LBCL
https://www.mdedge.com/hematology-oncology/article/255765/b-cell-lymphoma/fda-approves-liso-cel-second-line-therapy-lbcl
Sharon Worcester

Jun 27th, 2022 - Lisocabtagene maraleucel, also known as liso-cel (Breyanzi), has been approved by the Food and Drug Administration for the second-line treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). This expanded indicati.

see more →

Drugs  1 results see all →

Clinicaltrials.gov  87 results

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03484702

Jun 24th, 2022 - This is a study to determine the efficacy and safety of JCAR017 in adult participants with aggressive B-cell NHL. The study will enroll participants in Europe and Japan with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS; de no...

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT03255018

Jun 24th, 2022 - Background: Gray-zone lymphomas (GZL) are rare, aggressive lymphomas that share clinical and biological features of diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma Standard upfront therapy for GZL is dose-intensive chemotherapy, though ...

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
https://clinicaltrials.gov/ct2/show/NCT04947319

Jun 21st, 2022 - This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens...

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01399372

Jun 21st, 2022 - OBJECTIVES: Primary To determine median progression-free survival (PFS) in both arms on an intent-to-treat basis. Secondary To determine overall survival (OS) defined as the interval from randomization to death due to any cause. To determine treat...

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
https://clinicaltrials.gov/ct2/show/NCT02498951

Jun 13th, 2022 - PRIMARY OBJECTIVE: I. To determine the effect of maintenance obinutuzumab on duration of response (partial response [PR] or complete response [CR]) in patients with CD20+ B-cell primary central nervous system lymphoma (PCNSL) who attain PR or CR t...

see more →

News  31 results

FDA approves liso-cel as second-line therapy for LBCL
https://www.mdedge.com/hematology-oncology/article/255765/b-cell-lymphoma/fda-approves-liso-cel-second-line-therapy-lbcl
Sharon Worcester

Jun 27th, 2022 - Lisocabtagene maraleucel, also known as liso-cel (Breyanzi), has been approved by the Food and Drug Administration for the second-line treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). This expanded indicati.

FDA Okays Liso-cel for Second Line in Large B-cell Lymphoma
https://www.medscape.com/viewarticle/976230

Jun 27th, 2022 - Lisocabtagene maraleucel, also known as liso-cel (Breyanzi), has been approved by the Food and Drug Administration for the second-line treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). This expanded indicati...

Liso-cel Continues to Demonstrate Clinical Responses in Relapsed/Refractory LBCL at 2-Year Follow-Up
https://www.onclive.com/view/liso-cel-continues-to-demonstrate-clinical-responses-in-relapsed-refractory-lbcl-at-2-year-follow-up

Apr 25th, 2022 - The utilization of lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with relapsed/refractory large B-cell lymphomas (LBCL) produced durable outcomes at a 2 years follow-up, according to results from the phase 1 TRANSCEND NHL 001 trial (NC...

CAR T-Cell Therapy Earns Indication for Lymphoma in First Relapse
https://www.medpagetoday.com/hematologyoncology/hematology/98024

Apr 4th, 2022 - The FDA approved the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta) as initial treatment for relapsed/refractory large B-cell lymphoma (LBCL). The action moves CAR T-cell therapy to the earliest approved...

Thiotepa-Based Conditioning Promising for Primary CNS Lymphoma
https://www.medpagetoday.com/hematologyoncology/lymphoma/92452

May 6th, 2021 - Two commonly used thiotepa-based conditioning regimens were associated with favorable outcomes among patients with primary central nervous system lymphoma (PCNSL) undergoing autologous hematopoietic cell transplant (AHCT), according to a retrospec...

see more →